Structure Therapeutics Inc. 8-K

What Happened
Structure Therapeutics announced the appointment of Matthew Lang as Chief Operating Officer and General Counsel, effective April 15, 2026. The company filed Form 8-K disclosing Mr. Lang’s role, background, pay package and equity awards. Mr. Lang joins from Metsera and previously held senior legal and business roles at Lyell, Myovant and Gilead.

Key Details

• Base salary of $560,000 per year and eligibility for an annual discretionary bonus with a 40% target of base salary; no pro-ration for the 2026 bonus.
• Equity grants at target: stock option to purchase 223,776 ordinary shares (74,592 ADSs), RSUs for 184,614 ordinary shares (61,538 ADSs), and PSUs for 46,155 ordinary shares (15,385 ADSs).
• Vesting: option vests 25% at 1 year then monthly over 36 months; RSUs vest quarterly over four years (25% each year); PSUs split into three milestone tranches (25% by 12/31/2027, 25% by 9/30/2028, 50% by 6/30/2029) with actual payout 75%–125% of target depending on timing, and zero if milestones aren’t met.
• Employment is at-will; Mr. Lang will enter the company’s standard indemnification agreement. The full Employment Agreement will be filed as an exhibit to the company’s 10-Q for the quarter ending June 30, 2026.

Why It Matters
This 8-K signals a senior executive addition to Structure Therapeutics’ leadership team, combining legal and operating responsibilities in one role. Investors should note the compensation structure emphasizes equity and milestone-based incentives (PSUs), aligning pay with company performance and specific development milestones through mid-2029. The filing is a routine disclosure of an executive change and related pay terms rather than a financial-results filing.